Saturday 7 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue: +58.1%
EPS: +142.2%
Free cash flow: +43.5%

Quarter to September 2026, against a year earlier

94.01 5.67 +6.42%

Follow KNSA

Alert me

Market cap: $6.9B
P/E: 65.9×
Fwd P/E: 67.8×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a P/E ratio of 65.9×. Over the past ten years it has ranged from 0.0× (June 2025) to 646× (September 2025); the current reading is higher than 86% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and above the Healthcare sector median of 24.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KNSA/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Kiniksa Pharmaceuticals International, plc P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KNSA/metrics/pe-ratio">Kiniksa Pharmaceuticals International, plc (KNSA) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	51.6×	—
FY2024	0.0×	—
FY2023	97.5×	1,683.03%
FY2022	5.5×	—
FY2021	0.0×	—

Period	P/E ratio	Change
Sep 2026	52.3×	(12.43%)
Jun 2026	59.8×	21.64%
Mar 2026	49.1×	(4.71%)
Dec 2025	51.6×	(34.93%)
18 more quarters	Free account

Against its own ten years

Low 0.0× High 646×

Ten-year median 0.0×

Current reading's percentile 86

Company	P/E ratio
HIMS Hims & Hers Health, Inc. compare	n/m
ELAN Elanco Animal Health Incorporated compare	n/m
ALKS Alkermes plc compare	n/m
SUPN Indivior Pharmaceuticals Inc. compare	7.0×
LNTH Lantheus Holdings, Inc. compare	24.3×
LQDA Liquidia Corporation compare	28.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	38.2×
RDY Dr. Reddy's Laboratories Ltd compare	45.4×
KNSA Kiniksa Pharmaceuticals International, plc	65.9×
Drug Manufacturers Specialty & Generic industry median	20.5×
Healthcare sector median	24.5×
Market median	17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Kiniksa Pharmaceuticals International, plc (KNSA) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on KNSA

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on KNSA

Stockrow Weekly